AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.01 |
Market Cap | 19.86M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -8.39 |
PE Ratio (ttm) | -0.25 |
Forward PE | n/a |
Analyst | Buy |
Ask | 2.18 |
Volume | 271,845 |
Avg. Volume (20D) | 1,713,175 |
Open | 2.15 |
Previous Close | 2.12 |
Day's Range | 2.08 - 2.23 |
52-Week Range | 1.09 - 11.18 |
Beta | undefined |
About GOVX
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, ch...
Analyst Forecast
According to 6 analyst ratings, the average rating for GOVX stock is "Buy." The 12-month stock price forecast is $16.5, which is an increase of 683.85% from the latest price.
Next Earnings Release
Analysts project revenue of $920.00K, reflecting a n/a YoY growth and earnings per share of -0.95, making a -75.89% decrease YoY.
2 months ago · seekingalpha.com
GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call TranscriptGeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript